Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drugs, Devices, Diagnostics & Digital: Europe’s New R&D Venture Presents Its Agenda

Executive Summary

The EU’s new public-private partnership, the Innovative Health Initiative, plans to involve a wide range of stakeholders in research projects aimed at developing new drugs, diagnostics and medical devices. At its launch event this week, two of its top officials described how the venture would work, who could get involved, and the challenges in doing so.

You may also be interested in...



Goodbye IMI, Hello IHI: New EU Partnership Prepares To Invite Research Proposals

The new iteration of the EU’s successful public-private R&D partnership will seek to integrate pharmaceutical research with medical technology and digital health platforms to produce innovative cross-sectoral projects in areas such as drug/device combinations and AI-based diagnostics.

EFPIA On How To Prepare EU For Future Health Crises

A report from industry federation EFPIA and its Vaccines Europe arm says that R&D has produced safe and effective tools for tackling COVID-19 but that the EU needs to address a set of short- to medium-term priorities if it is to be in a position to tackle future health emergencies.

COVID-19 Summit Sees Progress On Test-And-Treat, IP Licensing, & Funding Commitments

Announcements at the second Global COVID-19 Summit included a technology licensing agreement for vaccine and diagnostic products developed by the US NIH, a new partnership to boost the use of testing and antiviral treatments in less wealthy countries, and a flurry of new funding pledges from organizations and companies alike.

Topics

UsernamePublicRestriction

Register

PS145601

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel